Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a common neurodegenerative disorder caused by genetic and environmental factors that results in degeneration of the nigrostriatal dopaminergic pathway in the brain. We analyzed neural cells generated from induced pluripotent stem cells (iPSCs) derived from PD patients and presymptomatic individuals carrying mutations in the PINK1 (PTEN-induced putative kinase 1) and LRRK2 (leucine-rich repeat kinase 2) genes, and compared them to those of healthy control subjects. We measured several aspects of mitochondrial responses in the iPSC-derived neural cells including production of reactive oxygen species, mitochondrial respiration, proton leakage, and intraneuronal movement of mitochondria. Cellular vulnerability associated with mitochondrial dysfunction in iPSC-derived neural cells from familial PD patients and at-risk individuals could be rescued with coenzyme Q(10), rapamycin, or the LRRK2 kinase inhibitor GW5074. Analysis of mitochondrial responses in iPSC-derived neural cells from PD patients carrying different mutations provides insight into convergence of cellular disease mechanisms between different familial forms of PD and highlights the importance of oxidative stress and mitochondrial dysfunction in this neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Moreover, PD patient iPSC-derived dopaminergic neurons harboring LRRK2 and PINK1 mutations showed impaired axonal outgrowth and deficient autophagic vacuole clearance which cause abnormal α-syn accumulation [38].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [38]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pharmacological capability of Coenzyme Q10, rapamycin, and LRRK2 kinase inhibitor GW5074 were found in iPSC-derived neural cells from PD patients with LRRK2 and PINK1 mutations [38].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 2×
“Subjects 3 and 4 were 59-year-old Caucasian twins (sister and brother) from a family with PD (family D) (9, 60).”
BackgroundSelf-citationCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405 · cited 1×
“Dominantly inherited mutations in LRRK2 are associated with familial PD (9, 10) that is clinically and pathologically similar, but not identical, to the more common late-onset idiopathic form of the disease (11–14).”
BackgroundThe substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756 · cited 1×
“Our data are consistent with the hypothesis of cell type–specific vulnerability developed for PD patients, where the midbrain DA neurons are more vulnerable than neighboring neuronal subtypes that also express genes associated with familial PD (1, 53, 54).”
ResultGenome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Self-citationPINK1-dependent recruitment of Parkin to mitochondria in mitophagy
Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L. A., Kim, J., May, J., Tocilescu, M. A., Liu, W., Ko, H. S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911187107 · Cited by 1,616
Self-citationBender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“For example, the agerelated accumulation of dysfunctional mitochondria (55, 56) can be mimicked using low doses of mitochondrial stressors, such as valinomycin or MPP, which create controlled, widespread mitochondrial damage within a cell population.”
BackgroundHealy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Self-citationSatake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · cited 1×
“We therefore decided to first examine mitochondrial dysfunction in iPSC-derived neural cells from patients with rare familial forms of PD to see whether there are commonalities in terms of vulnerabilities to chemical stressors and toxins (26).”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“In contrast, the OCRs show that the mitochondrial electron transport chain is intact in PD patient neural cells carrying LRRK2 mutations, but the reduced levels of basal respiration in these cells suggest that the increased kinase activity caused by the LRRK2 mutations reduces the availability of substrates for oxidat…”
Self-citationThe vacuolar (H+)-ATPases — nature's most versatile proton pumps
Nishi, T., & Forgac, M. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm729 · Cited by 1,197 · cited 1×
“Compared to healthy control neural cells, PD patient neural cells also showed increased sensitivity to concanamycin A, a specific inhibitor of vacuolar-type H-dependent adenosine triphosphatases (V-ATPases) that regulate autophagy and membrane transport (31, 32).”
BackgroundSmall molecule modulation of Smoothened activity
Chen, J. K., Taipale, J., Young, K. E., Maiti, T., & Beachy, P. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182542899 · Cited by 992 · cited 1×
“The iPSCs were differentiated with standard protocols (66) except that recombinant human SHH-C24II protein was replaced by a small-molecule agonist of Smoothened (1 mM, Enzo) (67, 68).”
MethodKraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 887
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Guzman, J. N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P. T., & Surmeier, D. J. (2010) · Nature · doi:10.1038/nature09536 · Cited by 843
Self-citationPathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., & Richardson, R. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1346 · Cited by 639
Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
Frei, B., Kim, M. C., & Ames, B. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4879 · Cited by 620 · cited 1×
“The rescue of PINK1 Q456X PD patient neural cells from low concentrations of valinomycin and concanamycin A by the antioxidant coenzyme Q10 and the LRRK2 inhibitor GW5074 is consistent with the hypothesis that loss of PINK1 leads to production of ROS through an LRRK2-associatedmechanism (15, 43, 44).”
BackgroundMicrotubule-Based Transport Systems in Neurons: The Roles of Kinesins and Dyneins
Goldstein, L. S. B., & Yang, Z. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.39 · Cited by 550 · cited 1×
“LRRK2 regulates the stability of neuronal microtubules that are required for efficient trafficking of mitochondria to energy-dependent regions within neurons (41, 42).”
BackgroundThe role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539 · cited 1×
“LRRK2 pathogenic mutations occur in the catalytic domains of this kinase—the G2019S mutation in the kinase domain and the R1441C/ G/H mutation in the guanosine triphosphatase domain—implicating altered LRRK2 kinase activity in PD pathogenesis (15, 16).”
BackgroundValente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., & Wood, N. W. (2001) · The American Journal of Human Genetics · doi:10.1086/319522 · Cited by 493
A functionally characterized test set of human induced pluripotent stem cells
Boulting, G. L., Kiskinis, E., Croft, G. F., Amoroso, M. W., Oakley, D. H., Wainger, B. J., Williams, D. J., Kahler, D. J., Yamaki, M., Davidow, L., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1783 · Cited by 489
Frank-Kamenetsky, M., Zhang, X. M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F. Y., Jones, S., Shulok, J., et al. (2002) · Journal of Biology · doi:10.1186/1475-4924-1-10 · Cited by 488 · cited 1×
“The iPSCs were differentiated with standard protocols (66) except that recombinant human SHH-C24II protein was replaced by a small-molecule agonist of Smoothened (1 mM, Enzo) (67, 68).”
MethodLive cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells
Chan, E. M., Ratanasirintrawoot, S., Park, I.-H., Manos, P. D., Loh, Y.-H., Huo, H., Miller, J. D., Hartung, O., Rho, J., Ince, T. A., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1580 · Cited by 487 · cited 2×
“S S1) (27, 62), and the genotype was confirmed for each iPSC clone.”
BackgroundMethodThe Regulation and Physiology of Mitochondrial Proton Leak
Divakaruni, A. S., & Brand, M. D. (2011) · Physiology · doi:10.1152/physiol.00046.2010 · Cited by 486 · cited 1×
“The findings suggest that iPSC-derived neural cells from PD patients carrying PINK1 mutations may use mitochondrial proton leakage to minimize oxidative damage due to loss of PINK1 activity (27, 35, 36).”
BackgroundRapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson's Disease
Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S., & Greene, L. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3944-09.2010 · Cited by 462
Self-citationDroese, S., Bindseil, K. U., Bowman, E. J., Siebers, A., Zeeck, A., & Altendorf, K. (1993) · Biochemistry · doi:10.1021/bi00066a008 · Cited by 416
A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease
Lesnick, T. G., Papapetropoulos, S., Mash, D. C., Ffrench-Mullen, J., Shehadeh, L., de Andrade, M., Henley, J. R., Rocca, W. A., Ahlskog, J. E., & Maraganore, D. M. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030098 · Cited by 411
Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411
Chung, C. Y., Koprich, J. B., Siddiqi, H., & Isacson, O. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5427-08.2009 · Cited by 391
Seibler, P., Graziotto, J., Jeong, H., Simunovic, F., Klein, C., & Krainc, D. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4441-10.2011 · Cited by 378
Self-citationChung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
Self-citationInhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Lee, B. D., Shin, J.-H., VanKampen, J., Petrucelli, L., West, A. B., Ko, H. S., Lee, Y.-I., Maguire-Zeiss, K. A., Bowers, W. J., Federoff, H. J., et al. (2010) · Nature Medicine · doi:10.1038/nm.2199 · Cited by 329
Self-citationRapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., & Whitworth, A. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2372 · Cited by 323 · cited 1×
“This contrasts with the neuroprotective effects of rapamycin observed in Drosophila carrying a PINK1 null mutation (48).”
ResultMitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2
Mortiboys, H., Johansen, K. K., Aasly, J. O., & Bandmann, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ff9685 · Cited by 307
Genetic Analysis of Pathways to Parkinson Disease
Hardy, J. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.014 · Cited by 274 · cited 1×
“S past decade, mutations in several genes have been shown to confer a significant risk of developing PD (7, 8).”
BackgroundAutosomal dominant parkinsonism associated with variable synuclein and tau pathology
Wszolek, Z. K., Pfeiffer, R. F., Tsuboi, Y., Uitti, R. J., McComb, R. D., Stoessl, A. J., Strongosky, A. J., Zimprich, A., Müller-Myhsok, B., Farrer, M. J., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000125015.06989.db · Cited by 266
Self-citationNovel PINK1 mutations in early‐onset parkinsonism
Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomiyama, H., Yoshino, H., Asahina, M., Kobayashi, S., Hassin‐Baer, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20251 · Cited by 245
Biochemical and pathological characterization of Lrrk2
Giasson, B. I., Covy, J. P., Bonini, N. M., Hurtig, H. I., Farrer, M. J., Trojanowski, J. Q., & Van Deerlin, V. M. (2006) · Annals of Neurology · doi:10.1002/ana.20791 · Cited by 238
Self-citationMutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts
Rakovic, A., Grünewald, A., Kottwitz, J., Brüggemann, N., Pramstaller, P. P., Lohmann, K., & Klein, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016746 · Cited by 235
Self-citationMalagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228
Pruszak, J., Ludwig, W., Blak, A., Alavian, K., & Isacson, O. (2009) · Stem Cells · doi:10.1002/stem.211 · Cited by 227
Novel PINK1 mutations in early-onset parkinsonism
波田野, 靖. (2005) · Medical Entomology and Zoology · Cited by 227
Cooper, O., Hargus, G., Deleidi, M., Blak, A., Osborn, T., Marlow, E., Lee, K., Levy, A., Perez-Torres, E., Yow, A., et al. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.06.017 · Cited by 226 · cited 3×
“The iPSCs were differentiated with standard protocols (66) except that recombinant human SHH-C24II protein was replaced by a small-molecule agonist of Smoothened (1 mM, Enzo) (67, 68).”
MethodSelf-citationVan Laar, V. S., Arnold, B., Cassady, S. J., Chu, C. T., Burton, E. A., & Berman, S. B. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq531 · Cited by 225
Gillardon, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06235.x · Cited by 221 · cited 1×
“LRRK2 regulates the stability of neuronal microtubules that are required for efficient trafficking of mitochondria to energy-dependent regions within neurons (41, 42).”
BackgroundClinical features of LRRK2‐associated Parkinson's disease in central Norway
Aasly, J. O., Toft, M., Fernandez‐Mata, I., Kachergus, J., Hulihan, M., White, L. R., & Farrer, M. (2005) · Annals of Neurology · doi:10.1002/ana.20456 · Cited by 191
Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities
Magrane, J., Hervias, I., Henning, M. S., Damiano, M., Kawamata, H., & Manfredi, G. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp421 · Cited by 170
Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons
Saha, A. R., Hill, J., Utton, M. A., Asuni, A. A., Ackerley, S., Grierson, A. J., Miller, C. C., Davies, A. M., Buchman, V. L., Anderton, B. H., et al. (2004) · Journal of Cell Science · doi:10.1242/jcs.00967 · Cited by 169
Stem Cells and Drug Discovery: The Beginning of a New Era?
Rubin, L. L. (2008) · Cell · doi:10.1016/j.cell.2008.02.010 · Cited by 165
Parkinson's disease: insights from pathways
Cookson, M. R., & Bandmann, O. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq167 · Cited by 162
Morfini, G., Pigino, G., Opalach, K., Serulle, Y., Moreira, J. E., Sugimori, M., Llinás, R. R., & Brady, S. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611231104 · Cited by 134
Hedrich, K., Hagenah, J., Djarmati, A., Hiller, A., Lohnau, T., Lasek, K., Grünewald, A., Hilker, R., Steinlechner, S., Boston, H., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.6.833 · Cited by 133 · cited 2×
“It is not clear whether PINK1 mutations cause the characteristic Lewy body inclusions that are found in most other forms of PD (21, 22).”
BackgroundSelf-citationPluripotent Stem Cells and Disease Modeling
Colman, A., & Dreesen, O. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.08.010 · Cited by 131
Rakovic, A., Grunewald, A., Seibler, P., Ramirez, A., Kock, N., Orolicki, S., Lohmann, K., & Klein, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq215 · Cited by 124
Self-citationMitochondrial Respiratory Dysfunction in Familiar Parkinsonism Associated with PINK1 Mutation
Piccoli, C., Sardanelli, A. M., Scrima, R., Ripoli, M. C., Quarato, G., D’Aprile, A., Bellomo, F., Scacco, S., Michele, G. D., Filla, A., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9729-2 · Cited by 109
Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Dürr, A., Tazir, M., Wszolek, Z. K., Uitti, R. J., Nichols, W. C., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1250 · Cited by 104
Self-citationChin, P. C., Liu, L., Morrison, B. E., Siddiq, A., Ratan, R. R., Bottiglieri, T., & D'Mello, S. R. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02530.x · Cited by 92
Edwards, Y. J. K., Beecham, G. W., Scott, W. K., Khuri, S., Bademci, G., Tekin, D., Martin, E. R., Jiang, Z., Mash, D. C., ffrench‐Mullen, J. M. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016917 · Cited by 84 · cited 1×
“Such variations may be found in genes implicated in familial PD (6, 23) or in genes in signaling pathways that have not yet been implicated in PD (3, 24).”
BackgroundBafilomycin A1 is a potassium ionophore that impairs mitochondrial functions
Teplova, V. V., Tonshin, A. A., Grigoriev, P. A., Saris, N.-E. L., & Salkinoja-Salonen, M. S. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9095-9 · Cited by 82
Genetic analysis of LRRK2 mutations in patients with Parkinson disease
Deng, H., Le, W., Guo, Y., Hunter, C., Xie, W., Huang, M., & Jankovic, J. J. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.09.017 · Cited by 70 · cited 1×
“Genomic PCR (for genotyping primer sequences, see table S2) and direct sequencing of the products confirmed the genotypes of the iPSC lines with standard methods as described (65).”
MethodPARK6-linked autosomal recessive early-onset parkinsonism in Asian populations
Hatano, Y., Sato, K., Elibol, B., Yoshino, H., Yamamura, Y., Bonifati, V., Shinotoh, H., Asahina, M., Kobayashi, S., Ng, A. R., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142258.29304.fe · Cited by 69
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations
Chen‐Plotkin, A. S., Yuan, W., Anderson, C., Wood, E. M., Hurtig, H. I., Clark, C. M., Miller, B. L., Lee, V. M.-Y., Trojanowski, J. Q., Grossman, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000280574.17166.26 · Cited by 67
Self-citationZhdanov, A. V., Dmitriev, R. I., & Papkovsky, D. B. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0502-8 · Cited by 57
CORTICOBASAL SYNDROME AND PRIMARY PROGRESSIVE APHASIA AS MANIFESTATIONS OF LRRK2 GENE MUTATIONS
Ross, O. A., Toft, M., & Haugarvoll, K. (2008) · Neurology · doi:10.1212/01.wnl.0000320511.30222.dd · Cited by 57
Self-citationDevelopment of Histocompatible Primate‐Induced Pluripotent Stem Cells for Neural Transplantation
Deleidi, M., Hargus, G., Hallett, P. J., Osborn, T. M., & Isacson, O. (2011) · Stem Cells · doi:10.1002/stem.662 · Cited by 53 · cited 1×
“Teratoma analyses were performed in nonobese diabetic/severe combined immunodeficient mice as described (64) (Applied StemCell).”
MethodSelf-citationBrustovetsky, T., Li, V., & Brustovetsky, N. (2009) · Cell Calcium · doi:10.1016/j.ceca.2009.03.017 · Cited by 52
The curious case of phenocopies in families with genetic Parkinson's disease
Klein, C., Chuang, R., Marras, C., & Lang, A. E. (2011) · Movement Disorders · doi:10.1002/mds.23853 · Cited by 47 · cited 1×
“The accumulation of genetic variants associated with PD may also explain the high incidence of shared clinical syndromes in family members who do not share the familial genetic mutation (25).”
BackgroundSelf-citationExamining Braak's hypothesis by imaging Parkinson's disease
Brooks, D. J. (2010) · Movement Disorders · doi:10.1002/mds.22720 · Cited by 41 · cited 1×
“Our data are consistent with the hypothesis of cell type–specific vulnerability developed for PD patients, where the midbrain DA neurons are more vulnerable than neighboring neuronal subtypes that also express genes associated with familial PD (1, 53, 54).”
ResultBiological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis
Grünewald, A., Breedveld, G. J., Lohmann-Hedrich, K., Rohé, C. F., König, I. R., Hagenah, J. M., Vanacore, N., Meco, G., Antonini, A., Goldwurm, S., et al. (2007) · Neurogenetics · doi:10.1007/s10048-006-0072-y · Cited by 26
Self-citationClinical and demographic characteristics of PINK1 mutation carriers—A meta‐analysis
Kasten, M., Weichert, C., Lohmann, K., & Klein, C. (2010) · Movement Disorders · doi:10.1002/mds.23031 · Cited by 20 · cited 1×
“It is not clear whether PINK1 mutations cause the characteristic Lewy body inclusions that are found in most other forms of PD (21, 22).”
BackgroundSelf-citation
Research works printed but not linked: 1
- 10.1093/hmg/ddi178 · DOI · Paper page
Cited by
Biological Functions of Autophagy Genes: A Disease Perspective
Levine, B., & Kroemer, G. (2019) · Cell · doi:10.1016/j.cell.2018.09.048 · Cited by 2,832
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019) · Molecules · doi:10.3390/molecules24081583 · Cited by 2,254
“It is also evidenced that neurons with mutations in protein LRRK2 are more vulnerable to mitochondrial toxins [119].”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
“Further, iPSC cells from LRRK2 mutant human subjects exhibit increased vulnerability to MPP+ [325].”
BackgroundInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Antioxidant and Oxidative Stress: A Mutual Interplay in Age-Related Diseases
Tan, B. L., Norhaizan, M. E., Liew, W.-P.-P., & Sulaiman Rahman, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01162 · Cited by 1,149
Metadata
- Authors
- Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T., Hargus, G., Deleidi, M., Lawson, T., Bogetofte, H., Perez-Torres, E., Clark, L., Moskowitz, C., Mazzulli, J., Chen, L., Volpicelli-Daley, L., Romero, N., Jiang, H., Uitti, R. J., Huang, Z., Opala, G., Scarffe, L. A., Dawson, V. L., Klein, C., Feng, J., Ross, O. A., Trojanowski, J. Q., Lee, V. M.-Y., Marder, K., Surmeier, D. J., Wszolek, Z. K., Przedborski, S., Krainc, D., Dawson, T. M., & Isacson, O.
- Affiliations
- Harvard University (US)
- Johns Hopkins University (US)
- Departments of Neurology, Psychiatry, and Pathology and Cell Biology, Sergievsky Center, Taub Institute and the Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA.
- Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.
- Northwestern University (US)
- Columbia University Irving Medical Center (US)
- Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
- University at Buffalo, State University of New York (US)
- Mayo Clinic in Florida (US)
- University of Florida (US)
- Medical University of Silesia (PL)
- University of Lübeck (DE)
- University of Pennsylvania (US)
- Departments of Neurology and Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
- Neuroregeneration Institute, McLean Hospital/Harvard Medical School, Belmont, MA 02478, USA.
- Corresponding author
- Cooper, Oliver
- Seo, Hyemyung
- Andrabi, Shaida
- Graziotto, John
- Sundberg, Maria
- McLean, Jesse R.
- Xie, Zhong
- Osborn, Teresia
- Hargus, Gunnar
- Deleidi, Michela
- Lawson, Tristan
- Bogetofte, Helle
- Perez-Torres, Eduardo
- Clark, Lorraine
- Moskowitz, Carol
- Mazzulli, Joseph
- Chen, Li
- Romero, Norma
- Jiang, Houbo
- Uitti, Ryan J.
- Scarffe, Leslie A.
- Dawson, Valina L.
- Feng, Jian
- Ross, Owen A.
- Trojanowski, John Q.
- Lee, Virginia M.-Y.
- Marder, Karen
- Surmeier, D. James
- Przedborski, Serge
- Krainc, Dimitri
- Dawson, Ted M.
- ORCID
- Cooper, Oliver
- Seo, Hyemyung
- Andrabi, Shaida
- Graziotto, John
- Sundberg, Maria
- Xie, Zhong
- Hargus, Gunnar
- Deleidi, Michela
- Bogetofte, Helle
- Clark, Lorraine
- Mazzulli, Joseph
- Chen, Li
- Jiang, Houbo
- Uitti, Ryan J.
- Scarffe, Leslie A.
- Dawson, Valina L.
- Klein, Christine
- Feng, Jian
- Ross, Owen A.
- Trojanowski, John Q.
- Lee, Virginia M.-Y.
- Marder, Karen
- Surmeier, D. James
- Przedborski, Serge
- Krainc, Dimitri
- Dawson, Ted M.
- Venue
- Science Translational Medicine
- Published
- 2012-07-04
- Volume
- 4
- Issue
- 141
- Pages
- 141ra90-141ra90
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3462009
- OpenAlex
- W2102424187
- Cited by
- 508
- References
- 72
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 13 · 2023: 22 · 2022: 37 · 2021: 36 · 2020: 39 · 2019: 42 · 2018: 52 · 2017: 47 · 2016: 50 · 2015: 52 · 2014: 50 · 2013: 36 · 2012: 6
- FWCI
- 29.75
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000064, 5rc2ns070276-02)
- National Institute of Neurological Disorders and Stroke (NS 38377, RC2-NS070276, NS057567, R56NS036630, 1RC2-NS070276, R01NS036630, U24NS078338, R01NS057567, R01NS061856, P50NS038377, P50NS072187)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- Parkinson's disease, familial Parkinson's disease, iPSC-derived neural cells, mitochondrial dysfunction, PINK1 mutations, LRRK2 mutations, coenzyme Q10, rapamycin, GW5074, LRRK2 inhibitors, reactive oxygen species, mitochondrial respiration, proton leak, mitochondrial dynamics, oxidative stress, presymptomatic carriers, dopaminergic neurons
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Humans, Indoles, Mitochondria, Neurons, Parkinson Disease, Phenols, Ubiquinone, Protein Serine-Threonine Kinases, Sirolimus, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.